Coya Therapeutics Q1 net loss $2.7M; ALS data halt progression; Dr. Reddy's deal

Coya Therapeutics, Inc.

2023-Q1 EPS reported -$0.28

Net loss of $2.7M ($0.28 per share) for Q1 2023 vs $1.7M loss in Q1 2022.
Cash and cash equivalents $16.3M as of March 31, 2023.
Positive proof-of-concept data for COYA 302 in ALS: halted disease progression at 24 weeks, minimal decline at 48 weeks.
Entered worldwide agreement with Dr. Reddy's: in-licensed abatacept biosimilar for COYA 302, out-licensed COYA 301 to Dr. Reddy's for certain territories.
Appointed Arun Swaminathan, Ph.D. as Chief Business Officer; plans to file IND for phase 2 ALS trial in H2 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Coya Therapeutics, Inc. reported the fiscal quarter ended March 31, 2023 results: net income $2.7 million.

Period: the fiscal quarter ended March 31, 2023
Net income: $2.7 million
Result: reported results

Exact text from the filing

Net loss was $2.7 million for the quarter ended March 31, 2023, compared to net loss of $1.7 million for the quarter ended March 31, 2022.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.